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Background: Obesity has been proposed as a risk factor to develop rheumatoid arthritis (RA) and it has been associated with a worse response to several disease modifying anti-rheumatic drugs (DMARDs). Objectives: To study the differences in baseline characteristics according to the body mass index (BMI) of patients in the PEARL (Princesa Early Arthritis Register Longitudinal) study. Methods: A total of 432 patients (69.1% female) of the PEARL cohort were included for this study. The register protocol comprises the collection of sociodemographic, disease-related and treatment data in five visits (baseline, 6, 12, 24 and 60 months) . The local ethics and clinical research committee approved the protocol and all patients sign an informed consent prior to their inclusion. For this study it was analyzed the baseline visit data from the 304 (70.37%) patients that met ACR 1987 criteria for RA after 2 years of follow-up, as well as those considered undifferentiated arthritis (UA) since other diagnoses were excluded. The WHO definition for low, normal weight, overweight and obesity (BMI <18.5, 18.5-25, 25-30 or ≥30 kg/m 2 respectively) was applied. ACPA (anticitrullinated peptide antibodies) were assessed by enzyme immunoassay (CCP2 Eurodiagnostica). HLA-DRB1 genotype was determined in 219 patients using specific HLADRB1 typing kits (Dynal RELI SSO). The presence of shared epitope (SE) was determined based on this genotyping. The statistical analysis was performed by using Stata 12.1. Chi-Square and Kruskal-Wallis tests were used for the bivariate analysis. A multivariate logistic regression was performed to determine which factors may be related to ACPA positivity, including BMI, age, sex, smoking habit, number of SE alleles and study level as independent variables. Results: Patients were 54.9 years old [44.2-67.5] (median [p25-p75]); disease duration was 5.3 months [3-8.4 ]. Table 1 shows the main variables significantly associated to BMI. In addition, we observed less ACPA positivity with increasing BMI (57% low weight vs. 43% in obese [p =0.08]), as well as a lower frequency of SE in patients with a higher BMI. The multivariate analysis confirmed that being smoker (ever or current) and carrying SE alleles is associated with the presence of ACPA. Adjusted by these variables, overweight and obesity were associated with lower probability of suffering an ACPA positive disease (OR 0.49, p=0.027 and OR 0.39, p=0.019 respectively). Background: Temporary interruption of RA therapy is common in clinical practice; therefore, rapid clearance and low immunogenicity may be useful DMARD attributes. Baricitinib (bari) is a non-biologic Janus kinase (JAK) 1 /JAK2 selective inhibitor with a pharmacokinetic half-life in RA patients of approximately 13 hours. It has demonstrated improved clinical efficacy compared to MTX, adalimumab and placebo (pbo) with a satisfactory safety profile when administered once daily to RA patients in 4 completed Phase 3 studies. Objectives: These analyses aimed to characterize temporary interruptions of study drug during these studies and explore the kinetics of RA symptoms during and following interruption. Methods: During bari Phase 3 studies, investigators were required to document temporary interruptions of study drug, including timing, reason and duration, using electronic case report forms. In 2 studies, patients recorded RA symptoms (duration and severity of morning joint stiffness, worst tiredness and worst joint pain) daily for 12 weeks. Post hoc analyses investigated changes in these scores among patients randomized at least 7 days prior to interruption, having an interruption that lasted at least 3 days, and retreated. Results: Across the 3 pbo-controlled studies, interruptions occurred in a larger proportion of patients with bari than pbo only in the biologic DMARD-inadequate responder (IR) study RA-BEACON. In the 2 active comparator-controlled studies, the lowest rates of interruption were in the bari monotherapy arm of the DMARDnaïve MTX-controlled RA-BEGIN study, and proportions were similar for bari and adalimumab in the MTX-IR study, RA-BEAM (Table 1) . Adverse events (predominantly non-serious, mild or moderate infections, most commonly of the respiratory tract) were the most frequent reason for interruption. Few patients interrupted for the reason of abnormal laboratory results. Most interruptions lasted for 2 weeks or less; in RA-BEAM, interruptions appeared shorter in duration for bari than for adalimumab. Diary measures indicated modest symptom increases during interruption compared to the last pre-interruption value, with a return to pre-interruption values or better after resumption of study drug (Table 2) . Conclusions: Consistent with its pharmacologic properties, brief temporary interruptions of bari during Phase 3 studies were associated with minor increases in RA symptoms, which resolved following resumption of therapy. A small molecule with a short half-life may offer advantages over injectable biologic therapies with respect to drug interruption for clinical cause in RA patients. 
